Biomarkers of Inflammation and Progression During Immunotherapy in Patients With Metastatic Renal Cell Carcinoma

Spisarová, Martina; Melichar, Bohuslav; Juráňová, Jarmila; Zemánková, Anežka; Adam, Tomáš; Matoušová, Kateřina; Javorská, Lenka; Krčmová, Lenka Kujovská; Turoňová, Dorota; Študentová, Hana

doi:10.21873/invivo.13091

Cited by 3 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, a decrease in NLR during treatment was a predictor of a longer OS (HR=0.34; 95%CI=0.20-0.56; p<0.001) (20). Therefore, NLR, similarly others factors like serum C-reactive protein (CRP), neopterin, and urinary neopterin, lower serum albumin and hemoglobin concentration, could be considered a reliable biomarkers of activation of immune response, associated with outcome in mRCC patients treated with ICI immunotherapy (21).…”

Section: Discussionmentioning

confidence: 99%

Bone Metastases in Renal Cell Carcinoma: Impact of Immunotherapy on Survival

GAMBALE,

PALMIERI,

ROSSI

et al. 2023

CDP

View full text Add to dashboard Cite

Background/Aim: We performed a multicenter retrospective observational study to investigate the impact of immune checkpoint inhibitors (ICIs) on the survival of patients with bone metastases (BMs) from renal cell cancer (RCC). Patients and Methods: A total of 98 patients with metastatic RCC (mRCC) treated with ICIs were retrospectively enrolled. All patients received standard treatments with nivolumab alone or in combination with ipilimumab from December 2015 to March 2022. The primary endpoint was median overall survival (OS). Results: Forty-three patients (44%) had radiological evidence of BMs. No statistically significant difference in OS was reported between the BM population and the entire population (p=0.254). Conclusion: Our study suggests some degree of ICI activity to treat patients with BMs from RCC, historically associated with a poorer prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Bone Metastases in Renal Cell Carcinoma: Impact of Immunotherapy on Survival

GAMBALE,

PALMIERI,

ROSSI

et al. 2023

CDP

View full text Add to dashboard Cite

show abstract

“…Prognostic factors, such as PD-L1 expression, for indicating those patients who could respond to IFN-alpha therapy and other immunotherapies in renal RCC should be studied (30,(66)(67)(68)(69). Recently, GWAS studies have pointed some single nucleotide polymorphisms (SNPs) and certain chromosomal gains and losses to be associated with the outcome of RCC (70,71).…”

Section: Progression-free Survival (Pfs)mentioning

confidence: 99%

Long-term Outcome With Prolonged Use of Interferon-alpha Administered Intermittently for Metastatic Renal Cell Carcinoma: A Phase II Study

et al. 2023

View full text Add to dashboard Cite

Background/Aim: Interferon-alpha (IFN-alpha) has shown survival benefits in metastatic renal cell carcinoma (mRCC), but the knowledge about long-term outcome is sparse. Additional knowledge is beneficial because IFN-alpha usage in combination therapy such as immune checkpoint inhibitor for mRCC is an area of interest. This is the longest follow-up concerning IFN-alpha treatment. Patients and Methods: A total of 117 metastatic renal cell cancer (mRCC) patients without prior chemotherapy were enrolled between 1994-2002 and followed-up until January 2022. The median follow-up was 18 months. After progression to IFN-alpha, the patients were not treated with tyrosine kinase, mTOR inhibitors or bevacizumab as these were not standard therapies at that time or the patients' performance status was too poor. Mean treatment duration was 11 months. Results: Median overall survival was 19.0 months, 5-year survival rate 16.2%, and 10year survival rate 9.0%. There were statistically significant differences in survival in response to treatment (log-rank test, p<0.001): median overall survival was 52.0 months for objective responses, 25.0 months for stable disease and 5.0 months for progressive disease. Proportion of 5-year survivors was 29% in low, 20% in intermediate, and 7% in high-risk groups, respectively (p=0.001). Conclusion: With prolonged INF-alpha treatment stable and responding patients can obtain late objective responses, long-lasting complete responses, and long-term outcome with acceptable toxicity. IFN-alpha is an alternative therapy when multiple treatment lines are used for mRCC and an interesting option to study for combined therapies such as immune checkpoint inhibitor-based therapies.Renal cell carcinoma (RCC) accounts for 2-3% of all diagnosed malignancies worldwide, and in some Northern/Central Europe countries even 5% (1). The annual increase in the incidence of RCC, since the 1970's, has been in the range of 2% to 4% (2, 3), which has been attributed to the frequent use of imaging techniques, the increasing prevalence of cigarette smoking, and obesity (3, 4). However, a recent plateau in RCC incidence rates has also been reported in some countries (3). Hereditary kidney cancers may account for at least 5-8% of all kidney cancers (5). At diagnosis, 20-30% of RCC patients have metastases. Half of patients diagnosed with localized disease will later have a recurrence of their cancer: of these, two thirds within the first year and the majority within 5 years (6). Although the increase of RCC incidence is due to localized RCC, also metastasized RCC (mRCC) has increased slightly (3, 7). Currently mRCC accounts for approximately 15% of all RCC (7).Currently, treatments in RCC are evolving. There are several effective therapeutic options for mRCC patients. When selecting the treatment, prognostic factors, other illnesses, and side-affects are taken into consideration. IFNalpha treatment is an option as first line treatment for mRCC patients with bevacizumab especially for the good and intermediate prognostic risk ...

show abstract